At Cellistic, our people are at the heart of turning iPSC-derived cell therapies into clinical reality.
In this series, we meet the experts who make the difference — sharing their insights, challenges, and what drives them every day.
Each week, one of our experts answers three questions, offering a closer look at the minds shaping the future of iPSC-based therapies — and making the difference that counts to bring those therapies to patients.
November 3, 2025
She Makes the Difference: Cécile Augereau, PhD
Cell Therapy Innovation Director
To open this series, we spent time with Cécile Augereau, our Director of Cell Therapy Innovation, to understand what it really looks like to build iPSC-derived therapies from idea to clinical-ready reality.
In this conversation, Cécile reflects on what makes working on allogeneic iPSC technology so genuinely exciting from a scientific standpoint, and the part of scaling iPSC-based processes that most people don’t fully see until they’re in it.
"The fact that you can just take one cell from the body, reprogram this cell into a pluripotent stem cell and from this iPS generate all the cell types of the body is just incredible, right?
Watch the interview to hear Cécile’s perspective first hand
Up next: November 10, 2025
Next in our Science in Person series, we'll be talking with Hind Ghezraoui, Principal Scientist in our Cell Line Development team.
She’ll be sharing her perspective on advanced genome engineering approaches for iPSCs — a topic she’ll also explore further in an upcoming Cellistic webinar.
Curious? Check the webinar information here.